JP2023543132A - シクロデキストリンによるコレステロール結晶塞栓症の予防方法 - Google Patents

シクロデキストリンによるコレステロール結晶塞栓症の予防方法 Download PDF

Info

Publication number
JP2023543132A
JP2023543132A JP2023513678A JP2023513678A JP2023543132A JP 2023543132 A JP2023543132 A JP 2023543132A JP 2023513678 A JP2023513678 A JP 2023513678A JP 2023513678 A JP2023513678 A JP 2023513678A JP 2023543132 A JP2023543132 A JP 2023543132A
Authority
JP
Japan
Prior art keywords
cyclodextrin
individual
amount
hydroxypropyl
cholesterol crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543132A5 (https=
Inventor
カーウィン，ダイアナ
カム，ジェイソン
Original Assignee
ベレン セラピューティクス ピー．ビー．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベレン セラピューティクス ピー．ビー．シー． filed Critical ベレン セラピューティクス ピー．ビー．シー．
Publication of JP2023543132A publication Critical patent/JP2023543132A/ja
Publication of JP2023543132A5 publication Critical patent/JP2023543132A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513678A 2020-08-27 2021-08-27 シクロデキストリンによるコレステロール結晶塞栓症の予防方法 Pending JP2023543132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071243P 2020-08-27 2020-08-27
US63/071,243 2020-08-27
PCT/US2021/048075 WO2022047244A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Publications (2)

Publication Number Publication Date
JP2023543132A true JP2023543132A (ja) 2023-10-13
JP2023543132A5 JP2023543132A5 (https=) 2024-08-27

Family

ID=80352440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513678A Pending JP2023543132A (ja) 2020-08-27 2021-08-27 シクロデキストリンによるコレステロール結晶塞栓症の予防方法

Country Status (11)

Country Link
US (1) US20230302042A1 (https=)
EP (1) EP4203973A4 (https=)
JP (1) JP2023543132A (https=)
KR (1) KR20230096976A (https=)
CN (1) CN116635007A (https=)
AU (1) AU2021331485A1 (https=)
BR (1) BR112023003490A2 (https=)
CA (1) CA3190764A1 (https=)
IL (1) IL300881A (https=)
MX (1) MX2023002420A (https=)
WO (1) WO2022047244A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREBE, A., TARGETING CHOLESTEROL CRYSTALS IN ATHEROSCLEROSIS WITH CHOLESTEROL SOLUBILIZING 2-HYDROXYPROPYL-Β-C, JPN6025030773, 2016, pages 1 - 132, ISSN: 0005807608 *
THE JOURNAL OF BIOMEDICAL RESEARCH, vol. 31(2), JPN6025030772, 2017, pages 82 - 94, ISSN: 0005807609 *

Also Published As

Publication number Publication date
KR20230096976A (ko) 2023-06-30
CA3190764A1 (en) 2022-03-03
EP4203973A4 (en) 2024-08-21
US20230302042A1 (en) 2023-09-28
BR112023003490A2 (pt) 2023-05-09
MX2023002420A (es) 2023-07-11
IL300881A (en) 2023-04-01
CN116635007A (zh) 2023-08-22
EP4203973A1 (en) 2023-07-05
AU2021331485A1 (en) 2023-03-23
WO2022047244A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7487264B2 (ja) ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
JP2023543132A (ja) シクロデキストリンによるコレステロール結晶塞栓症の予防方法
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
TW202342072A (zh) 以環糊精治療高三酸甘油脂血症之方法
HK40097424A (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303